Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, Belaya Z, Feelders RA, Vila G, Houde G, Walia R, Izquierdo M, Roughton M, Pedroncelli AM, Biller BMK. Fleseriu M, et al. Among authors: shimatsu a. Eur J Endocrinol. 2022 Sep 16;187(4):531-541. doi: 10.1530/EJE-22-0317. Print 2022 Oct 1. Eur J Endocrinol. 2022. PMID: 35980235 Free PMC article.
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Among authors: shimatsu a. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, Suzuki A, Sato M, Shimatsu A. Tanaka T, et al. Among authors: shimatsu a. Endocr J. 2020 Aug 28;67(8):841-852. doi: 10.1507/endocrj.EJ19-0617. Epub 2020 May 1. Endocr J. 2020. PMID: 32378529 Free article. Clinical Trial.
Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
Shimatsu A, Nakamura A, Takahashi Y, Fujio S, Satoh F, Tahara S, Nishioka H, Takano K, Yamashita M, Arima H, Tominaga A, Tateishi S, Matsushita Y. Shimatsu A, et al. Endocr J. 2021 Jul 28;68(7):791-805. doi: 10.1507/endocrj.EJ20-0707. Epub 2021 Mar 11. Endocr J. 2021. PMID: 33692246 Free article. Clinical Trial.
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Yuno A, Kenmotsu Y, Takahashi Y, Nomoto H, Kameda H, Cho KY, Nakamura A, Yamashita Y, Nakamura J, Nakakubo S, Kamada K, Suzuki M, Sugino H, Inoshita N, Konno S, Miyoshi H, Atsumi T, Sawamura Y, Shimatsu A. Yuno A, et al. Among authors: shimatsu a. Endocr J. 2021 Apr 28;68(4):477-484. doi: 10.1507/endocrj.EJ20-0613. Epub 2020 Dec 24. Endocr J. 2021. PMID: 33361650 Free article.
360 results